The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.
The campaigns also claim the product can prevent spread of MRSA and norovirus.
The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act.
The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.
The Role of Positive Distraction in Pediatric Design
Healthcare Waste is Fueling America's Debt
Prairie Lakes Healthcare System to Rebrand Following Sanford Health Merger
How Digital Technologies Are Reshaping Performance in Healthcare Facilities
The Role of Plumbing in Healthcare-Associated Infections